Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's

This page shows the latest Alzheimer's news and features for those working in and with pharma, biotech and healthcare.

After mixed signals, will Eisai and Biogen press on with Alzheimers hopeful?

After mixed signals, will Eisai and Biogen press on with Alzheimer’s hopeful?

After mixed signals, will Eisai and Biogen press on with Alzheimer’ s hopeful? ... Sub-study aimed at addressing doubts raises more questions. New data was presented yesterday on one of the few promising late-stage Alzheimer’s disease candidates

Latest news

  • US ‘unicorn’ Samumed on track with lead arthritis drug US ‘unicorn’ Samumed on track with lead arthritis drug

    Samumed will showcase another of its pipeline drugs this week at the Clinical Trials on Alzheimer’s Disease (CTAD) Congress, which started in Barcelona yesterday. ... Preclinical data on DYRK1A inhibitor SM07883, which the company says is a potential

  • Spinraza lifts Biogen ahead of Alzheimer’s data Spinraza lifts Biogen ahead of Alzheimers data

    Predictably, a lot of questions from analysts on the company’s third-quarter results call focused on Biogen’s Alzheimer’s disease candidates aducanumab and BAN2401, which will have new updates ... reported at the Clinical Trials on Alzheimer’s

  • Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

    The new biotech's executive chairman Arie Belldegrun and CEO David Cheng brought cell therapy specialist Kite Pharma from a start-up to an almost $12bn buyout, and investors are confident ... That's why the IPO is a record-breaker, surpassing the $315m

  • Theranexus takes Alzheimer’s drug combo into clinic Theranexus takes Alzheimers drug combo into clinic

    Theranexus takes Alzheimer’ s drug combo into clinic. 150-subject phase 1b trial to start at eight centres in France. ... Theranexus has been the green light to start trials of an Alzheimer’s disease therapy (AD) based on two generic medicines by the

  • Tox trouble stalls Sosei/Allergan Alzheimer’s drug Tox trouble stalls Sosei/Allergan Alzheimers drug

    Tox trouble stalls Sosei/Allergan Alzheimer’ s drug. Surprise findings from primate studies. ... of muscarinic agonists for the treatment of major neurological disorders, including Alzheimer’s disease.

More from news
Approximately 101 fully matching, plus 422 partially matching documents found.

Latest Intelligence

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    Key considerations for disease- modifying Parkinson’ s disease trials. ‘Lessons learnt from Alzheimer’s trials could help in Parkinson’s drug development’. ... The design of such neuroprotective studies may benefit from the lessons learned in

  • Tackling a formidable foe Tackling a formidable foe

    MAVENCLAD’S short-course oral therapy profile is a bonus to a condition freighted with psychological drag-weights. ... s or Alzheimer’s.

  • What can pharma learn from the charity sector? What can pharma learn from the charity sector?

    the charity sector (or third sector, as it’s also known) to better support its patients. ... Dr Doug Brown, Chief Policy and Research Officer at Alzheimer’s Society, explains how co-creation is an essential part of its research process:.

  • Deal Watch January 2018

    leukaemia (ALL), Juno's share price had been in the low $20s for several months. ... Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at

  • The good, the bad and the ugly The good, the bad and the ugly

    Alzheimer’s - where 98% of drugs fail Phase III trials. ... This was largely thanks to Eliquis overtaking Bayer’s Xarelto as the leader in novel oral anticoagulants.

More from intelligence
Approximately 1 fully matching, plus 38 partially matching documents found.

Latest appointments

  • Cognite strengthens team with two new additions Cognite strengthens team with two new additions

    She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science

  • Metrion Biosciences establishes scientific advisory board Metrion Biosciences establishes scientific advisory board

    The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011. ... Alzheimer's disease.

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    In his new role, Prof De Strooper will work with the institute's founding partners - the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK - to develop new therapeutics

More from appointments
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics